{"id":35951,"date":"2026-08-10T17:40:00","date_gmt":"2026-08-10T12:10:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35951"},"modified":"2026-08-10T12:40:24","modified_gmt":"2026-08-10T07:10:24","slug":"benlysta-vs-gazyva","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva","title":{"rendered":"BENLYSTA vs GAZYVA: Who Wins the Battle for Lupus Nephritis Treatment?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a7ab3bc7d838\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a7ab3bc7d838\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#BENLYSTA_The_Established_Benchmark_in_Lupus_Care\" >BENLYSTA: The Established Benchmark in Lupus Care<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#GAZYVA_The_Newer_Entrant_Reshaping_the_Conversation\" >GAZYVA: The Newer Entrant Reshaping the Conversation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#BENLYSTA_vs_GAZYVA_Key_Differences\" >BENLYSTA vs GAZYVA: Key Differences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#Market_Outlook_and_Implications_Entrenchment_Meets_Emerging_Competition\" >Market Outlook and Implications: Entrenchment Meets Emerging Competition<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#Payer_Considerations\" >Payer Considerations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#Uptake_Barriers\" >Uptake Barriers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#Where_GAZYVA_Could_Challenge_BENLYSTA\" >Where GAZYVA Could Challenge BENLYSTA<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>Lupus nephritis treatment is entering a new phase, shifting from broad immunosuppressants to targeted biologics, with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors.<\/em><\/li>\n\n\n\n<li><em>BENLYSTA is the established benchmark, with over a decade of clinical use in SLE and approvals for lupus nephritis since 2020, supported by strong real-world efficacy, safety data, and physician familiarity.<\/em><\/li>\n\n\n\n<li><em>GAZYVA, approved for lupus nephritis in 2025, is a newer entrant backed by positive Phase II\/III trial data and FDA Breakthrough Therapy designation, signaling strong clinical potential.<\/em><\/li>\n\n\n\n<li><em>BENLYSTA offers both subcutaneous (at-home) and intravenous (infusion) dosing, enhancing convenience and adherence, whereas GAZYVA is IV-only, requiring clinic-based administration.<\/em><\/li>\n<\/ul>\n\n\n\n<p>Lupus nephritis has long been one of the most challenging manifestations of systemic lupus erythematosus (SLE) to treat, and for years, treatment options were limited to broad immunosuppressants that came with significant tradeoffs. That&#8217;s changing fast. As the <a href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-treatment-outlook\">lupus nephritis treatment market<\/a> matures, two biologics are increasingly being weighed against each other by clinicians, payers, and pharma strategists alike: <strong>BENLYSTA (belimumab) and GAZYVA (obinutuzumab)<\/strong>.<\/p>\n\n\n\n<p>Why does this comparison matter right now? Because the lupus nephritis market is at an inflection point. BENLYSTA has spent over a decade building trust as a targeted therapy, while GAZYVA, originally developed in oncology, is emerging as a serious contender with a differentiated mechanism of action. Understanding how these two lupus nephritis drugs stack up isn&#8217;t just an academic exercise; it&#8217;s shaping treatment algorithms, market access strategy, and the direction of ongoing lupus and lupus nephritis clinical trials disease mechanism alignment research.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-benlysta-the-established-benchmark-in-lupus-care\"><span class=\"ez-toc-section\" id=\"BENLYSTA_The_Established_Benchmark_in_Lupus_Care\"><\/span><strong>BENLYSTA: The Established Benchmark in Lupus Care<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>GSK\u2019s BENLYSTA (belimumab)<\/strong> has long served as the reference biologic in lupus therapeutics, and it remains one of the most recognizable names in the lupus nephritis drugs landscape. It was first approved in the US in 2011 for <a href=\"https:\/\/www.delveinsight.com\/blog\/systemic-lupus-erythematosus-treatment-landscape\">systemic lupus erythematosus treatment<\/a>, with lupus nephritis approval following in 2020; Europe followed in 2021, and Japan in 2017 for SLE and 2021 for lupus nephritis. In the UK, belimumab is recognized by NICE for active autoantibody-positive SLE, while lupus nephritis access is tied to broader European authorization and local reimbursement pathways.<\/p>\n\n\n\n<p>As a <strong>BLyS-specific inhibitor<\/strong>, belimumab works by blocking B-lymphocyte stimulator, a protein that supports the survival of autoreactive B cells and drives autoantibody production in SLE and lupus nephritis. The drug is available in both subcutaneous and intravenous formulations, which gives clinicians flexibility between at-home maintenance and infusion-center administration. The SC regimen consists of 400 mg administered once weekly during the first month, followed by a maintenance dose of 200 mg once weekly.&nbsp;<\/p>\n\n\n\n<p>In the United States, the unit cost of a 200 mg SC dose was estimated at <strong>USD 1,153<\/strong>. The IV formulation is administered at 10 mg\/kg every two weeks for the initial three doses and every four weeks thereafter. The unit cost of a 400 mg IV dose was <strong>USD 2,161<\/strong>. Treatment costs for the IV formulation were calculated separately for adult and pediatric patients and subsequently averaged. All US cost estimates were originally based on 2023 prices and were adjusted to 2020 price levels for the analysis.<\/p>\n\n\n\n<p>Several factors have solidified BENLYSTA&#8217;s position as the benchmark therapy for SLE. Its long-standing clinical presence, supported by more than a decade of real-world efficacy and safety data in SLE, followed by its expansion into lupus nephritis, has established a strong foundation of clinical confidence. In addition, BENLYSTA is available in both IV and SC formulations, providing flexibility for patients and healthcare providers by accommodating both infusion-center administration and at-home self-injection. This versatility, combined with extensive physician experience, has strengthened prescriber confidence among rheumatologists and nephrologists, reinforcing BENLYSTA&#8217;s role as a preferred first-line biologic across many treatment pathways. This combination of mechanistic specificity, dosing flexibility, and clinical familiarity is exactly why BENLYSTA continues to anchor a large share of the lupus nephritis treatment market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gazyva-the-newer-entrant-reshaping-the-conversation\"><span class=\"ez-toc-section\" id=\"GAZYVA_The_Newer_Entrant_Reshaping_the_Conversation\"><\/span><strong>GAZYVA: The Newer Entrant Reshaping the Conversation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Roche\u2019s GAZYVA has recently entered the lupus nephritis treatment landscape, positioning it as a newer therapeutic option rather than an established standard of care. It is an <strong>anti-CD20 monoclonal antibody<\/strong> that directly depletes CD20-positive B cells rather than modulating a survival signal like belimumab. Originally developed as an oncology therapy, the anti-CD20 monoclonal antibody received approvals for multiple hematologic malignancies beginning with the United States in 2013, followed by approvals across the European Union, the United Kingdom, and Japan. Building on encouraging results from the <strong>Phase II NOBILITY study<\/strong> and the pivotal <strong>Phase III REGENCY trial<\/strong>, GAZYVA received its first regulatory <a href=\"https:\/\/www.delveinsight.com\/blog\/gazyva-for-lupus-nephritis-treatment\">approval for lupus nephritis<\/a> in the United States in 2025, marking the first anti-CD20 therapy specifically approved for this indication.<\/p>\n\n\n\n<p>During its lupus nephritis development program, obinutuzumab was also granted <strong>US FDA Breakthrough Therapy designation<\/strong>, recognizing its potential to offer meaningful improvements over existing therapies. The therapy is administered exclusively through intravenous (IV) infusion, requiring delivery in a clinical or infusion-center setting, unlike BENLYSTA, which also offers a subcutaneous (SC) formulation for greater convenience. Mechanistically, GAZYVA differentiates itself by directly depleting B cells, rather than inhibiting B-cell survival signals, providing a distinct and potentially complementary strategy for interrupting the autoimmune processes that drive lupus nephritis.<\/p>\n\n\n\n<p>For specialists watching how lupus and <a href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs\">lupus nephritis clinical trials<\/a> disease mechanism alignment data evolves, GAZYVA represents a chance to test whether more aggressive B-cell depletion translates into deeper, more durable renal responses.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"469\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-in-USD-Million-1024x469.webp\" alt=\"Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-(in-USD-Million)\" class=\"wp-image-35955\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-in-USD-Million-1024x469.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-in-USD-Million-300x137.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-in-USD-Million-150x69.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-in-USD-Million-768x352.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-in-USD-Million-1536x703.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/Market-Size-of-BENLYSTA-and-GAZYVA-GAZYVARO-in-the-7MM-in-USD-Million.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-benlysta-vs-gazyva-key-differences\"><span class=\"ez-toc-section\" id=\"BENLYSTA_vs_GAZYVA_Key_Differences\"><\/span><strong>BENLYSTA vs GAZYVA: Key Differences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>When specialists evaluate these two lupus nephritis drugs side by side, four dimensions consistently drive the decision:<\/p>\n\n\n\n<p><strong>Mechanism of Action: <\/strong>BENLYSTA inhibits BLyS, indirectly reducing autoreactive B-cell survival. GAZYVA takes a more direct route, binding CD20 to deplete B-cells outright. This distinction matters clinically; indirect suppression versus direct depletion can translate into different onset speeds, depth of immune modulation, and relapse patterns.<\/p>\n\n\n\n<p><strong>Administration and Dosing:<\/strong> BENLYSTA&#8217;s dual IV\/SC availability gives it an edge in convenience, particularly for patients who prefer at-home dosing after an initial IV phase. GAZYVA, as an infusion-only therapy, requires more frequent clinical visits, which may influence patient preference and adherence in real-world settings.<\/p>\n\n\n\n<p><strong>Clinical Positioning: <\/strong>BENLYSTA is generally positioned as a foundational, often first-line, biologic for SLE and lupus nephritis. GAZYVA is emerging as an option for patients seeking a different mechanistic approach, potentially as an alternative or add-on where B-cell depletion is prioritized.<\/p>\n\n\n\n<p><strong>Safety and Tolerability:<\/strong> Both drugs carry immunosuppression-related risks, including infection susceptibility, but their safety profiles diverge based on mechanism. BENLYSTA&#8217;s long track record provides a well-characterized safety picture, while GAZYVA&#8217;s profile, shaped initially by oncology use, is still being fully mapped out in the lupus nephritis population through ongoing trials and post-marketing surveillance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook-and-implications-entrenchment-meets-emerging-competition\"><span class=\"ez-toc-section\" id=\"Market_Outlook_and_Implications_Entrenchment_Meets_Emerging_Competition\"><\/span><strong>Market Outlook and Implications: Entrenchment Meets Emerging Competition<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The broader lupus nephritis treatment market is expanding as diagnostic awareness improves and the pipeline of biologics targeting B-cell pathways grows deeper. Within this landscape, BENLYSTA&#8217;s entrenched position is hard to overstate, it benefits from years of physician trust, payer familiarity, and a dosing flexibility that newer entrants are still working to match.<\/p>\n\n\n\n<p>That said, GAZYVA&#8217;s mechanistic differentiation gives it real potential to capture share, particularly as specialists actively look for more effective options for patients who don&#8217;t achieve adequate renal response on existing therapies. As more lupus and lupus nephritis clinical trials disease mechanism alignment data matures, GAZYVA could carve out a defined niche, either as a second-line option or, depending on <a href=\"https:\/\/www.delveinsight.com\/blog\/emerging-lupus-nephritis-therapies\">future lupus nephritis trial outcomes<\/a>, a therapy considered earlier in the treatment algorithm.<\/p>\n\n\n\n<p>For companies and investors tracking the lupus nephritis market, the coming years will likely be defined by head-to-head data readouts, real-world evidence accumulation, and how payers respond to a growing menu of lupus nephritis drugs competing for the same patient population.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-payer-considerations\"><span class=\"ez-toc-section\" id=\"Payer_Considerations\"><\/span><strong>Payer Considerations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Formulary placement will be a decisive factor in how quickly GAZYVA gains ground. BENLYSTA&#8217;s long tenure means it typically sits on established prior-authorization pathways, with payers already comfortable with its cost-effectiveness data and step-therapy positioning. GAZYVA, as a newer entrant to lupus nephritis, will need to build a comparable body of health-economic evidence before payers treat it as an equivalent first-line option rather than a therapy reserved for step-therapy failures. Given that GAZYVA is infusion-only, site-of-care reimbursement policies, and how generously payers cover infusion-center visits versus SC self-administration, will also shape its relative cost position in the lupus nephritis treatment market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-uptake-barriers\"><span class=\"ez-toc-section\" id=\"Uptake_Barriers\"><\/span><strong>Uptake Barriers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Beyond reimbursement, several practical factors could slow GAZYVA&#8217;s adoption curve. Its infusion-only administration adds a logistical burden, more frequent clinic visits, infusion-chair availability, and scheduling constraints, compared to BENLYSTA&#8217;s option for at-home SC dosing. Prescriber inertia is another factor: rheumatologists and nephrologists have over a decade of comfort managing patients on belimumab, and shifting entrenched treatment algorithms typically requires compelling head-to-head or long-term renal outcome data. Until GAZYVA accumulates a deeper real-world safety and efficacy record specific to lupus nephritis, many specialists are likely to reserve it for patients who aren&#8217;t responding adequately to existing therapy rather than reaching for it as an initial choice.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-where-gazyva-could-challenge-benlysta\"><span class=\"ez-toc-section\" id=\"Where_GAZYVA_Could_Challenge_BENLYSTA\"><\/span><strong>Where GAZYVA Could Challenge BENLYSTA<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Despite these headwinds, GAZYVA is well positioned to compete in specific patient segments rather than across the board. Patients with more severe or refractory lupus nephritis, particularly those who show an inadequate renal response to BLyS inhibition, represent a natural entry point, since GAZYVA&#8217;s direct B-cell depletion offers a mechanistically distinct option rather than simply another BLyS-pathway therapy. Younger patients or those earlier in their disease course, where specialists may prioritize a more aggressive approach to prevent long-term renal damage, could also be a segment worth watching as lupus and lupus nephritis clinical trials disease mechanism alignment data continues to build the case for earlier use. If GAZYVA can demonstrate durable renal response rates in these populations, it has a credible path to challenging BENLYSTA&#8217;s dominance in defined corners of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market\">lupus nephritis market<\/a>, even without displacing it as the broad first-line standard.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>BENLYSTA and GAZYVA represent two different philosophies for tackling the same underlying problem: an immune system that has turned against the kidneys. One is the seasoned, flexible benchmark; the other is the mechanistically distinct challenger with momentum on its side. Neither is likely to fully displace the other in the near term; instead, they&#8217;re more likely to carve out complementary roles as physicians tailor treatment to individual patient biology. As the lupus nephritis treatment market continues to evolve, one thing is clear: the days of a single dominant therapy are numbered, and patients stand to benefit from having more, and more targeted, options on the table.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/lupus-nephritis-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/05100449\/Lupus-Nephritis-Market-Assessment-1024x194.png\" alt=\"Lupus-Nephritis-Market-Assessment\" class=\"wp-image-31617\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/05100449\/Lupus-Nephritis-Market-Assessment-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/05100449\/Lupus-Nephritis-Market-Assessment-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/05100449\/Lupus-Nephritis-Market-Assessment-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/05100449\/Lupus-Nephritis-Market-Assessment-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/05100449\/Lupus-Nephritis-Market-Assessment-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/05100449\/Lupus-Nephritis-Market-Assessment.png 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary Lupus nephritis has long been one of the most challenging manifestations of systemic lupus erythematosus (SLE) to treat, and for years, treatment options were limited to broad immunosuppressants that came with significant tradeoffs. That&#8217;s changing fast. As the lupus nephritis treatment market matures, two biologics are increasingly being weighed against each other by clinicians, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35953,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[23069,23070,22745,6248,22750,6250,17782,6249,22392,721],"industry":[17225],"therapeutic_areas":[17230],"class_list":["post-35951","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-benlysta","tag-benlysta-vs-gazyva","tag-gazyva","tag-lupus-nephritis","tag-lupus-nephritis-drugs","tag-lupus-nephritis-market","tag-lupus-nephritis-pipeline","tag-lupus-nephritis-therapy","tag-sle-treatment","tag-systemic-lupus-erythematosus","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BENLYSTA vs GAZYVA: The Ultimate Lupus Nephritis Face-Off<\/title>\n<meta name=\"description\" content=\"Lupus nephritis treatment is entering a new phase with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BENLYSTA vs GAZYVA: The Ultimate Lupus Nephritis Face-Off\" \/>\n<meta property=\"og:description\" content=\"Lupus nephritis treatment is entering a new phase with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T12:10:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/benlysta-vs-gazyva.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BENLYSTA vs GAZYVA: The Ultimate Lupus Nephritis Face-Off","description":"Lupus nephritis treatment is entering a new phase with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva","og_locale":"en_US","og_type":"article","og_title":"BENLYSTA vs GAZYVA: The Ultimate Lupus Nephritis Face-Off","og_description":"Lupus nephritis treatment is entering a new phase with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors.","og_url":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-08-10T12:10:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/benlysta-vs-gazyva.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"BENLYSTA vs GAZYVA: Who Wins the Battle for Lupus Nephritis Treatment?","datePublished":"2026-08-10T12:10:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva"},"wordCount":1743,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/benlysta-vs-gazyva.webp","keywords":["BENLYSTA","BENLYSTA vs GAZYVA","GAZYVA","Lupus nephritis","Lupus Nephritis Drugs","Lupus nephritis market","Lupus Nephritis Pipeline","Lupus nephritis therapy","SLE Treatment","Systemic Lupus Erythematosus"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva","url":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva","name":"BENLYSTA vs GAZYVA: The Ultimate Lupus Nephritis Face-Off","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/benlysta-vs-gazyva.webp","datePublished":"2026-08-10T12:10:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Lupus nephritis treatment is entering a new phase with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/benlysta-vs-gazyva#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/benlysta-vs-gazyva.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/benlysta-vs-gazyva.webp","width":466,"height":284,"caption":"benlysta-vs-gazyva"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/08\/benlysta-vs-gazyva-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BENLYSTA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">BENLYSTA vs GAZYVA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GAZYVA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus Nephritis Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SLE Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BENLYSTA<\/span>","<span class=\"advgb-post-tax-term\">BENLYSTA vs GAZYVA<\/span>","<span class=\"advgb-post-tax-term\">GAZYVA<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis<\/span>","<span class=\"advgb-post-tax-term\">Lupus Nephritis Drugs<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis market<\/span>","<span class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/span>","<span class=\"advgb-post-tax-term\">SLE Treatment<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 12 hours ago","modified":"Updated 17 hours ago"},"absolute_dates":{"created":"Posted on Aug 10, 2026","modified":"Updated on Aug 10, 2026"},"absolute_dates_time":{"created":"Posted on Aug 10, 2026 5:40 pm","modified":"Updated on Aug 10, 2026 12:40 pm"},"featured_img_caption":"benlysta-vs-gazyva","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35951","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35951"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35951\/revisions"}],"predecessor-version":[{"id":35956,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35951\/revisions\/35956"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35953"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35951"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35951"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35951"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35951"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35951"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}